Health
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer – FierceBiotech
Georgetown researchers reported that combining BioXcel’s DPP inhibitor talabostat with a PD-1 blocker in mouse models of pancreatic…
When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with…
Continue Reading
-
Noosa News21 hours agoBrisbane radio station refers to Senator Fatima Payman as ‘slag’
-
General21 hours agoNewcastle man pleads guilty to possessing 34,000 child abuse images and 13 bestiality videos
-
Noosa News23 hours agoGold Coast teenager charged after allegedly stabbing female Uber driver outside Westfield Coomera
-
Business10 hours ago5 things to watch on the ASX 200 on Thursday 4 September 2025